Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
ABBV-324 is a type of drug called an antibody-drug conjugate (ADC). ADCs are composed of an antibody made from a specific cell line chemically linked to a drug. The antibody binds to specific proteins on certain types of cells, including cancer cells. The linked drug enters these cells and destroys them, with a lower risk of harming other cells. ABBV-324 is given intravenously (by vein).
The purpose of this study is to find the highest dose of the drug alectinib that can be given safely in children and adolescents with solid tumors or brain and spinal cord cancers that persist after treatment and have a genetic change called an ALK gene fusion. With this gene fusion, the ALK gene attaches to part of another gene.
In this study, researchers are comparing early treatment with venetoclax and obinutuzumab versus delayed treatment with these two medications in patients with newly diagnosed high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are not experiencing symptoms. Starting treatment with these drugs early (before patients have symptoms) may be more effective than delaying treatment until symptoms emerge.
Researchers are doing this study to learn if lung chemoembolization is safe and works well in people with lung cancer. The people in this study have non-small cell lung cancer that keeps growing after chemotherapy. Moreover, it cannot be cured with surgery or radiation therapy.
Researchers are assessing blinatumomab with dasatinib or imatinib and standard chemotherapy to treat leukemia. The people in this study have Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia (B-ALL).
The purpose of this study is to assess the safety and effectiveness of the investigational drug LNS8801 with and without pembrolizumab immunotherapy in people with advanced melanoma. LNS8801 works to reduce levels of a growth protein called MYC. By reducing these levels, LNS8801 may slow the growth of cancer, shrink the cancer, and help the immune system remove cancer from the body. Pembrolizumab boosts the ability of the immune system to find and kill cancer cells.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to find the best dose of TORL-1-23 to use in people with advanced solid tumors. The people in this study have solid tumors that have spread and cannot be successfully treated with standard therapies.
PF-07799544 and PF-07799933 both work by blocking proteins that promote melanoma growth. PF-07799544 blocks a family of proteins called MEK and PF-07799933 inhibits the BRAF protein. Both drugs are taken orally (by mouth).
Researchers want to find the best dose of DS-2243a to use in people with solid tumors. The people in this study have these solid tumors, which have spread beyond their original location:
